| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
ORIGINAL ARTICLES |
4-mm) Melanoma: Should We Be Doing It?
From the Winship Cancer Institute (GWC, DRM, AH, CAS, CC), Emory University School of Medicine; and Department of Biostatistics, Rollins School of Public Health (RHL), Emory University, Atlanta, Georgia.
Correspondence: Address correspondence and reprint requests to: Grant W. Carlson, MD, Winship Cancer Institute, 1365B Clifton Rd., Atlanta, GA 30322; Fax: 404-778-4255; E-mail: grant_carlson{at}emory.org
Background: Thick (
4-mm) primary melanomas are believed to be associated with a high incidence of occult distant metastases. The use of sentinel lymph node (SLN) mapping and biopsy in the treatment lesions has been questioned.
Methods: A retrospective review of a computerized database identified 114 patients who underwent successful SLN mapping and biopsy from January 1, 1994, to December 31, 1999. Records were reviewed for clinicopathologic features of the patients and their tumors. Survival curves were constructed from Kaplan-Meier estimates and analyzed with log-rank tests and Cox proportional hazards modeling.
Results: There were 75 men and 39 women with a mean age of 57 years (range, 24–85 years). The primary tumor sites were head and neck (n = 29; 25.4%), trunk (n = 44; 38.6%), and extremities (n = 41; 36%). Tumor thickness ranged from 4 to 17 mm (median, 5.2 mm; mean, 6.3 mm). Ulceration was present in 40 (35.1%) tumors. Thirty-seven patients (32.5%) had a positive SLN biopsy, and 18 of these patients (48.6%) had a single tumor-positive lymph node after dissection. The mean follow-up was 37.8 months. The overall 3-year survival for SLN-negative patients was 82%, versus 57% for SLN-positive patients (P = .006). Lymph node status and tumor ulceration were independent predictors of overall survival in multivariate Cox regression analysis.
Conclusions: The pathologic status of the SLN in patients with thick melanomas is a strong independent prognostic factor for survival, and SLN mapping should be routinely performed.
Key Words: Sentinel lymph node • Thick melanoma • Prognostic factors • Distant metastasis
This article has been cited by other articles:
 |
|
 |
|
  S. N. Markovic, L. A. Erickson, R. D. Rao, R. H. Weenig, B. A. Pockaj, A. Bardia, C. M. Vachon, S. E. Schild, R. R. McWilliams, J. L. Hand, et al. Malignant Melanoma in the 21st Century, Part 2: Staging, Prognosis, and Treatment Mayo Clin. Proc., April 1, 2007; 82(4): 490 - 513. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. R. Scoggins, M. I. Ross, D. S. Reintgen, R. D. Noyes, J. S. Goydos, P. D. Beitsch, M. M. Urist, S. Ariyan, B. S. Davidson, J. J. Sussman, et al. Prospective Multi-Institutional Study of Reverse Transcriptase Polymerase Chain Reaction for Molecular Staging of Melanoma J. Clin. Oncol., June 20, 2006; 24(18): 2849 - 2857. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. I. Ross Early-stage melanoma: staging criteria and prognostic modeling. Clin. Cancer Res., April 1, 2006; 12(7): 2312s - 2319s. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. F. Thompson and H. M. Shaw Is Sentinel Lymph Node Biopsy Appropriate in Patients With Thin Melanomas: Too Early To Tell? Ann. Surg. Oncol., March 1, 2006; 13(3): 279 - 281. [Full Text] [PDF]
|
|
|
|
|
|
A. M. M. Eggermont Reducing the Need for Sentinel Node Procedures by Ultrasound Examination of Regional Lymph Nodes Ann. Surg. Oncol., January 1, 2005; 12(1): 3 - 5. [Full Text] [PDF]
|
|
|
|
 |
|
 H. Tsao, M. B. Atkins, and A. J. Sober Management of Cutaneous Melanoma N. Engl. J. Med., September 2, 2004; 351(10): 998 - 1012. [Full Text] [PDF]
|
|
|
|
|
|
G. W. Carlson Editorial: Age and the Incidence of Sentinel Lymph Node Metastases in Melanoma Ann. Surg. Oncol., March 1, 2004; 11(3): 236 - 237. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
